托西利祖马布单疗法或与甲索特雷克萨特联合治疗类风湿性关节炎:一项随机临床试验
Tian Liu1, Li Wang2, Xiao Zhang3
1Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
JAMA network open
|May 19, 2025
概括
在中国的一项大型试验中,单独或与甲状腺素合并的皮下托西利祖马布 (tocilizumab) 与单独的甲状腺素相比,显著改善了类风湿性关节炎 (RA) 的结果. 托西利祖马布表现出良好的安全性,为RA患者提供了新的治疗选择.
科学领域:
- 类风湿病学 类风湿病学
- 临床试验 临床试验
- 免疫学 免疫学 免疫学
背景情况:
- 类风湿性关节炎 (RA) 患者往往对常规合成疾病修饰性抗风湿药物 (csDMARDs) 的反应不足.
- 较新的治疗选择对于有效管理RA至关重要.
- 皮下托西利祖马布 (TCZ) 单疗与TCZ结合甲醇 (MTX) 和MTX单疗的比较疗效和安全性数据有限.
研究的目的:
- 评估皮下TCZ单疗,TCZ-MTX组合和MTX单疗在对csDMARDs反应不足的RA患者的疗效和安全性.
主要方法:
- 一个大规模的,双盲的,在中国进行的3期随机临床试验.
- 成年人 (18-70岁) 患有中度至严重的活性RA被随机分配给TCZ-MTX,TCZ-安慰剂或MTX-安慰剂24周.
- 主要疗效终点是美国风湿病学学院在24周的20%改善 (ACR20);安全性被监测了56周.
主要成果:
- 在第24周,TCZ-MTX (52.9%) 和TCZ-安慰剂 (50.0%) 的ACR20应答率与MTX-安慰剂 (25.0%) 相比显著更高.
- 在持续使用TCZ治疗的患者中,在24周的延长阶段,疗效保持或改善.
- 对于tocilizumab没有发现新的安全信号.
结论:
- 皮下托西利祖马布,作为单一疗法或与甲醇合,对于具有不充分的csDMARD反应的RA患者,优于甲醇单一疗法.
- 托西利祖马布在本研究人群中表现出耐受性良好的安全性.
- 建议对不同种族和地区的人群进行进一步的研究,以确认TCZ的疗效和安全性,特别是作为单一疗法.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
130
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
130
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Drugs for Treatment of Ulcerative Colitis in IBD
116
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
116
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Inflammatory Bowel Disease IV: Pharmacological Management
86
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
86


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)